静注用リポプロスタグランデイン(PG) E_1製剤の比較

概要

論文の詳細を見る
The comparison study was performed with 3 kinds of Lipo PGE_1 (5μg/ml) preparations (Formulation A, B, and C), which are now used in clinical. Under alkali condition, Lipo PGE_1 (5μg/ml) preparations in combination with physiological solution containing calcium ion were susceptible to stop dropping because of the formation of aggregates. There was a difference of feasibility to form aggregates among these preparations. The percentage of PGE_1 in the LM (lipid microspheres) was 68.8% (Formulation A) when determined by filtration with the pore size of 0.1μm, and the respective value (%) of Formulation B and Formulation C was 43.0% and 13.9%. This indicates that the latter formulations were significantly susceptible to leak from the LM. PGE_1 can induce an extensive irritation. The potency of irritation was the most in Formulation C. This seems similar with the result of LM retention of PGE_1. PGE_1 increased the blood now. Formulation A reached the peak by 2.27 fold, which was significantly higher than Formulation C and PGE_1 alone (PGE_1-cyclodextrin, PGE_1-CD). The peak was also significantly higher in Formulation B than that of PGE_1-CD. The AUC value of blood flow rate showed a significant increase in Formulation A and Formulation B as compared to that of PGE_1-CD. Drug retention in the LM can be a determinant factor for drug distribution and pharmacological effect. This study indicates that there can be some differences among Lipo PGE_1 preparations, which have the same drug dose.
2007-08-01

静注用リポプロスタグランデイン(PG) E_1製剤の比較

スポンサーリンク

概要

著者

関連論文

スポンサーリンク